TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33651291
Drug: Mycorrhizal treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycorrhizal treatments (Funneliformis mosseae and Claroideoglomus etunicatum)
Study: 34247160
Drug: Oral frailty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral frailty measures program (12 weeks)
Study: 616280550
Drug: NRB (non-rebreather
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRB (non-rebreather mask) with flush rate oxygen (>40 L/min)
Study: 32182353
Drug: Daily cash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cash incentives
Study: 34378853
Drug: Tapered Implants
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tapered Implants (TIs)
Study: 34378853
Drug: Straight Implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Straight Implants (SIs)
Study: 34378853
Drug: Tapered Implants
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tapered Implants (TIs) and Straight Implants (SIs)
Study: 32931412
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg iron supplementation
Study: 32931412
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg iron supplementation
Study: 35451117
Drug: Water exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water exchange colonoscopy with infused water volume during insertion ≥ 1000 mL
Study: 33131095
Drug: Revaprazan 200
Normalized name: Revaprazan
DrugBank: Revaprazan (DB16308)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revaprazan 200 mg
Study: 32921535
Drug: 2% Chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Chlorhexidine (CHG) bathing daily during the intervention period (n = 1501)
Study: 35835631
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition and some control of the obstruction
Study: 35835631
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of the obstruction only
Study: 33858205
Drug: Corticosteroid (CS)
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (CS) injection: 20 mg of triamcinolone
Study: 33858205
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) injection: 2.5 mL of HA
Study: 33858205
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NS) injection: 2.5 mL of NS
Study: 35240044
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg bolus)
Study: 35240044
Drug: Moderate-dose unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose unfractionated heparin (5000 IU bolus followed by 1250 IU/h for 6 h)
Study: 35240044
Drug: Low-dose unfractionated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose unfractionated heparin (5000 IU bolus followed by 500 IU/h for 6 h)
Study: 35240044
Drug: No unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: No unfractionated heparin
Study: 33795826
Drug: Higher thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher thoracic radiotherapy dose (≥ 60 Gy)
Study: 35412592
Drug: Standard educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard educational materials in combination with web-based decision support tools
Study: 34625027
Drug: Capillary haemoglobin
Normalized name: Artemisia capillaris leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capillary haemoglobin measurement using a haemoglobinometer on a monthly basis
Study: 33566129
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum 299v administered for 60 days
Study: 33566129
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 60 days
Study: 32877582
Drug: Sodium phenylbutyrate‐taurursodiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium phenylbutyrate‐taurursodiol (3 g of sodium phenylbutyrate and 1 g of taurursodiol, administered once a day for 3 weeks and then twice a day)
Study: 35190815
Drug: 60 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 Gy radiation dose with concurrent chemotherapy (docetaxel 25 mg/m2; cisplatin 25 mg/m2)
Study: 35190815
Drug: 50 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 Gy radiation dose with concurrent chemotherapy (docetaxel 25 mg/m2; cisplatin 25 mg/m2)
Study: 33400004
Drug: Long-term glucocorticoid
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term glucocorticoid treatment
Study: 34016484
Drug: Polypill treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill treatment
Study: 35687008
Drug: Walnut intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut intake (15% of daily energy from walnuts)
Study: 33155675
Drug: efavirenz-based-ART after
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: efavirenz-based-ART after 4 weeks of rifampicin-based anti-TB therapy
Study: 33155675
Drug: efavirenz-based-ART after
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: efavirenz-based-ART after 8 weeks of rifampicin-based anti-TB therapy
Study: 33155675
Drug: rifampicin only
Normalized name: Rifampicin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: rifampicin only therapy for 4 weeks
Study: 33155675
Drug: rifampicin only
Normalized name: Rifampicin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: rifampicin only therapy for 8 weeks
Study: 35441931
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray plus oral antidepressant (AD)
Study: 35441931
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus oral antidepressant (AD)
Study: 36018037
Drug: Polypill (aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill (aspirin 100 mg, ramipril 2.5/5/10 mg, atorvastatin 20/40 mg)
Study: 32044752
Drug: Constant Therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant Therapy, a remotely delivered, cloud‐based rehabilitation program for speech-language disorders, duration: first 20 weeks of program access.
Study: 35987683
Drug: Lavender essence
Normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lavender essence inhalation
Study: 32465406
Drug: ECP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECP treatment (16 treatments in the first three months)
Study: 32465406
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard triple immunosuppression: tacrolimus, mycophenolate mofetil, and steroids)
Study: 34939347
Drug: Jintiange capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jintiange capsule for 3 months
Study: 34939347
Drug: Conventional postoperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional postoperative treatment
Study: 35761367
Drug: High-volume haemodiafiltration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume haemodiafiltration (aiming for 21+ L of substitution fluid adjusted for body surface area)
Study: 33148945
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein oral nutrition supplement containing HMB
Study: 35580297
Drug: Aumolertinib (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aumolertinib (110 mg once daily)
Study: 35580297
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg once daily)
Study: 34967165
Drug: Fosfomycin trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin trometamol + Canephron N (2 tablets t.i.d. for 2 weeks)
Study: 34967165
Drug: Fosfomycin trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin trometamol (3 g, single dose)
Study: 34114918
Drug: Longvida® optimized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longvida® optimized curcumin (1.0 g/day)
Study: 32966051
Drug: Alternative lowest-dose
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative lowest-dose route
Study: 34144486
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg daily for a median of 28 days
Study: 35664504
Drug: Functional kinematic
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional kinematic therapy
Study: 36829111
Drug: 10-µg FAKHRAVAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-µg FAKHRAVAC vaccine
Study: 36116775
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg of dexamethasone per day for 1 to 2 days
Study: 36116775
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg of dexamethasone per day for 1 to 2 days
Study: 36116775
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg of dexamethasone
Study: 36116775
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg of dexamethasone
Study: 34015036
Drug: Salbutamol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (2 puffs of 200 μg) 30 min before anesthesia induction and 30 min before surgery completion
Study: 33345816
Drug: Intravenous protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous protocol (intravenous paracetamol 3 times daily with oral ibuprofen twice daily)
Study: 33345816
Drug: Oral protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral protocol (oral paracetamol 3 times daily with oral ibuprofen twice daily)
Study: 33345816
Drug: On-demand protocol
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand protocol (oral paracetamol or ibuprofen or dipyrone based on visual analog scale)
Study: 33345816
Drug: Intravenous protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous protocol
Study: 33345816
Drug: Oral protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral protocol
Study: 33245749
Drug: CDR132L (0.32,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDR132L (0.32, 1, 3, and 10 mg/kg body weight)
Study: 33245749
Drug: CDR132L (≥1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDR132L (≥1 mg/kg)
Study: 33472201
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) until the 36th week of gestation
Study: 36155316
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health intervention for 24 weeks
Study: 33012187
Drug: New experimental
Approvals — FDA: no, EMA: no, PMDA: no
Description: New experimental drugs and drug combinations
Study: 33977736
Drug: Tamsulosin hydrochloride
Normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin hydrochloride sustained-release capsules (for urinary dysfunction in both groups)
Study: 32708894
Drug: Ibuprofen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (2 × 00 mg)
Study: 33340917
Drug: 6-week online
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6-week online Cognitive Behavioral Therapy for Insomnia (CBT-I) program
Study: 34366847
Drug: TQ-F3083 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ-F3083 (2 to 160 mg)
Study: 34366847
Drug: TQ-F3083 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ-F3083 (multiple doses for 7 days)
Study: 34366847
Drug: TQ-F3083 (20–160
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ-F3083 (20–160 mg cohorts)
Study: 35614467
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with budesonide/glycopyrronium/formoterol fumarate dihydrate
Study: 34628720
Drug: Single-dose napabucasin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose napabucasin (80-1200 mg)
Study: 34628720
Drug: Single-dose napabucasin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose napabucasin (240-1200 mg)
Study: 34628720
Drug: Single-dose napabucasin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose napabucasin (240-720 mg)
Study: 34628720
Drug: Single-dose napabucasin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose napabucasin
Study: 32223688
Drug: Direct rigid
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct rigid laryngoscope during suspension laryngoscopy (SL) procedures
Study: 32453996
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (intensive bi-manual treatment)
Study: 33439831
Drug: Atosiban (competitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atosiban (competitive antagonist of oxytocin and vasopressin receptors)
Study: 33439831
Drug: Vasopressin (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressin (not administered)
Study: 34334790
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal (61 g fat)
Study: 34334790
Drug: Low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat meal (10 g fat)
Study: 34427941
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oxycodone
Study: 33190135
Drug: Enoxaparin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (0.4 mg daily for 10 days)
Study: 33190135
Drug: Anticoagulants (meta-analysis)
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants (meta-analysis)
Study: 36106651
Drug: Enhanced physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced physical activity intervention (standard postoperative physical therapy plus goal setting, problem-solving, and motivational interviewing techniques)
Study: 36106651
Drug: Standard postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard postoperative physical therapy only (control group)
Study: 37818279
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment adherence
Study: 35339234
Drug: Astegolimab (490
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astegolimab (490 mg subcutaneous every 4 weeks for 44 weeks)
Study: 35339234
Drug: Placebo (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneous every 4 weeks for 44 weeks)
Study: 32512380
Drug: Continuous ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ropivacaine (0.2%) at 10 mL/h for 48 h
Study: 33991350
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg every 12 hours for 14 days)
Study: 33991350
Drug: Bedaquiline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedaquiline (400 mg once daily for 2 weeks, followed by 200 mg twice a week for 46 weeks) with clarithromycin
Study: 33991350
Drug: Bedaquiline monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedaquiline monotherapy (400 mg once daily for 2 weeks, followed by 200 mg 3 times a week for 46 weeks)
Study: 34169613
Drug: PDA-002 (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDA-002 (low-dose 3 × 10^6 cells)
Study: 34169613
Drug: PDA-002 (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDA-002 (high-dose 30 × 10^6 cells)
Study: 32259301
Drug: Oral stimulation
Normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral stimulation intervention
Study: 32383285
Drug: Starter containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starter containing 160 g/kg CP (65 g/kg RUP, based on DM)
Study: 32383285
Drug: Starter containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starter containing 180 g/kg CP (65 g/kg RUP, based on DM)
Study: 32383285
Drug: Starter containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starter containing 200 g/kg CP (62 g/kg RUP, based on DM)
Study: 37004887
Drug: Placebo (monotherapy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (monotherapy)
Study: 36169918
Drug: Resveratrol and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol and myoinositol (1000 mg each, twice daily for 12 weeks)
Study: 36169918
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and pioglitazone (500 mg and 15 mg respectively, twice daily for 12 weeks)
Study: 34119717
Drug: Standard Prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Prolonged Exposure (SPE; 10 weekly 90-min sessions)
Study: 34119717
Drug: Massed Prolonged
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massed Prolonged Exposure (MPE; 10 daily 90-min sessions)
Study: 32191766
Drug: 1:2 dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:2 dextrose solution (HYPO)
Study: 32191766
Drug: Hartmann's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hartmann's solution (ISO)
Study: 33363447
Drug: Optimal medicinal
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optimal medicinal therapy (OMT)
Study: 33409843
Drug: Hydrotherapy program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrotherapy program based on McKenzie and Williams therapy, performed individually 3 days per week for 20 sessions.
Study: 34279777
Drug: Classroom-centered intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classroom-centered intervention (CC)
Study: 32087610
Drug: LifeStories video
Approvals — FDA: no, EMA: no, PMDA: no
Description: LifeStories video self-help intervention based on acceptance and commitment therapy (ACT), used over a period of 4 weeks
Study: 32087610
Drug: LifeStories video
Approvals — FDA: no, EMA: no, PMDA: no
Description: LifeStories video self-help intervention based on acceptance and commitment therapy (ACT)
Study: 35979768
Drug: Cervical vertebra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical vertebra pulling therapy (once a week, 4 times total)
Study: 35979768
Drug: Sitting traction
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitting traction therapy (once a week, 4 times total)
Study: 35979768
Drug: Cervical vertebra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical vertebra pulling therapy
Study: 35979768
Drug: Sitting traction
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitting traction therapy
Study: 34311473
Drug: Deep Convolutional
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep Convolutional Neural Network (DCNN) using Med3D with data augmentation (DA) and global average pooling (GAP) techniques
Study: 34311473
Drug: Native DCNN
Normalized name: Castanea sative leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native DCNN without data augmentation or global average pooling
Study: 33954911
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg dexamethasone phosphate (DEX-P)
Study: 33954911
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg betamethasone phosphate (BET-P)
Study: 32236718
Drug: No concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No concomitant antiplatelet therapy (APT)
Study: 35414108
Drug: Double injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double injection (DI) of local anesthetics (0.5% ropivacaine 24 mL)
Study: 35414108
Drug: Triple injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple injection (TI) of local anesthetics (0.5% ropivacaine 24 mL)
Study: 33390056
Drug: Methotrexate plus
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate plus intramuscular vitamin D (MtxD)
Study: 33340522
Drug: Higher anti-dopaminergic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher anti-dopaminergic medication dosage
Study: 35099998
Drug: Outpatient therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient therapy without antibiotics
Study: 36293136
Drug: Microencapsulated ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microencapsulated ferric saccharate (MFS) 60 mg/day for 14 days
Study: 36293136
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate (FS) 60 mg/day for 14 days
Study: 35891482
Drug: WEVEE VRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: WEVEE VRP vaccine (two doses, administered 28 days apart)
Study: 33975865
Drug: Prescription sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription sleep medications
Study: 33975865
Drug: Non-users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-users of prescription sleep medications
Study: 34747368
Drug: Tocilizumab (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (7 monthly doses)
Study: 33037681
Drug: 15-minute infusion
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-minute infusion of vincristine (VCR)
Study: 33037681
Drug: 3-hour infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-hour infusion of vincristine (VCR)
Study: 32544361
Drug: bivalent HPV‐16/18
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent HPV‐16/18 vaccine with a 1st interval of 28–40 d and a 2nd interval of 140–160 d
Study: 32544361
Drug: bivalent HPV‐16/18
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent HPV‐16/18 vaccine with a 1st interval of 41–50 d